Eli Lilly Non-GAAP EPS of $7.48 beats by $0.87, revenue of $24.4B beats by $1.78B (LLY:NYSE)

Eli Lilly reported Q3 Non-GAAP EPS of $7.48, exceeding estimates by $0.87, and revenue of $24.4B, up 38.6% Y/Y and beating by $1.78B. Growth was driven by Mounjaro and Zepbound, with revenue including $900M from a specific source.

Original reporting
Published Oct 29, 2026, 10:47 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 10:51 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$LLY
Bullish
high confidence
Mentioned
$LLY
Relevance
9/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$LLYBullishHigh
01

Why it matters

The earnings beat reinforces Lilly's growth narrative and may trigger buying interest.

02

Market read

Large‑cap pharma earnings beat with significant revenue outperformance.

03

What to watch

Potential supply‑chain constraints or upcoming patent cliffs could temper long‑term gains.

Relevance 9/10Novelty 9/10Timing: after-hours release

Background

Eli Lilly's Q3 2026 results highlight growth driven by Mounjaro and Zepbound.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Eli Lilly reported Q3 2026 Non‑GAAP EPS of $7.48 beating expectations by $0.87 and revenue of $24.4 B beating by $1.78 B.

Expected impact

likely upside as market prices in the earnings beat

Evidence & confidence

Both EPS and revenue significantly exceeded forecasts, indicating better-than-expected performance of key drugs.

Market effects

Biotech and pharma sector may see broader rally on strong earnings from a major player.

U.S. markets likely to open higher on biotech strength.

Global investors may adjust exposure to diabetes/obesity drug space.

Counterpoint

If guidance is muted, the beat may already be priced in, limiting upside.

Key entities

  • Eli Lilly

    Pharmaceutical manufacturer reporting Q3 earnings.

Related articles

$NVOLow

GLP-1 vision warning: Could demand be affected?

The FDA requires GLP-1 drugs to carry warnings about a potential increased risk of NAION, a condition that can cause vision loss. Analysis showed 6.4 cases per 100,000 person-years among users, though no causal link has been established. Experts believe the warnings will have limited impact on demand. Novo Nordisk and Eli Lilly, manufacturers of GLP-1 drugs, responded to the FDA's requirements, emphasizing patient safety and the lack of specific findings related to their medicines.

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$LLYMed

ACR: Retatrutide Beneficial in Adults With Painful Knee OA, Obesity

A study published in the New England Journal of Medicine found that retatrutide, developed by Eli Lilly, significantly reduced knee pain and body weight in adults with painful knee osteoarthritis and obesity compared to placebo. The trials showed mean WOMAC pain score reductions of -3.96 and -3.74 for 9mg and 12mg doses, respectively, versus -2.12 for placebo, and weight reductions of -20.0% and -23.7% versus -4.6%. Serious adverse events were more common with retatrutide.

$LLYMed

Health Canada approves Eli Lilly’s daily Foundayo pill for weight loss

Health Canada approved Eli Lilly's daily oral weight-loss pill, Foundayo, for adults with obesity or related conditions. The drug, expected in January, competes with Lilly's injectables and Novo Nordisk's Rybelsus. Foundayo offers meal flexibility and differs chemically from other GLP-1 drugs. Pricing and insurance coverage will impact patient choices, with clinical trials showing varying weight-loss results.

$NVOHigh

What to know about the new GLP-1 pills now on sale

Novo Nordisk's Wegovy and Lilly's Foundayo, oral GLP-1 weight loss pills, are now available in Australia. Experts anticipate increased demand but caution about long-term effects and misuse. Prices range from $250 to $395 monthly, comparable to injectable versions. Availability varies by pharmacy.